Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Y3MO
|
|||
Former ID |
DAP000400
|
|||
Drug Name |
Amikacin
|
|||
Synonyms |
Amicacin; Amikacina; Amikacine; Amikacinum; Amikavet; Amikin; Arikace; Briclin; Kaminax; Lukadin; Mikavir; AMIKACIN SULFATE; Amikacin Base; Amikacin Dihydrate; ANTIBIOTIC BB-K8; Amiglyde-V; Amikacin & Tumor Necrosis Factor; Amikacin (USP); Amikacina [INN-Spanish]; Amikacine [INN-French]; Amikacinum [INN-Latin]; Amikin(Disulfate); Antibiotic BB-K 8; BB-K 8; BB-K8; Amiglyde-V (TN); Amikacin (USP/INN); Amikacin [USAN:BAN:INN]; O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-6))-N(sup 3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->4)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->6))-N(3)-(4-amino-L-2-hydroxybutyryl)-2-deoxy-L-streptamine; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-D-streptamine; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide; (2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide; 1-N-(L(-)-gamma-Amino-alpha-hydroxybutyryl)kanamycin A
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Tuberculosis [ICD-11: 1B10-1B1Z; ICD-10: A15-A19, B90] | Investigative | [2] | ||
Therapeutic Class |
Antibiotics
|
|||
Company |
Abbott Laboratories
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H43N5O13
|
|||
Canonical SMILES |
C1C(C(C(C(C1NC(=O)C(CCN)O)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(C(C(C(O3)CN)O)O)O)N
|
|||
InChI |
1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1
|
|||
InChIKey |
LKCWBDHBTVXHDL-RMDFUYIESA-N
|
|||
CAS Number |
CAS 37517-28-5
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9038, 602892, 7978685, 8140488, 8175188, 11533325, 14886882, 17396714, 26057066, 29215141, 34679028, 46506386, 47734200, 47734201, 48182834, 48415546, 49699077, 50047827, 50105695, 56314316, 57312091, 57691603, 79044930, 96099940, 104234226, 104327437, 117570306, 123080686, 124766001, 125263960, 127284329, 127284330, 127284331, 127284332, 131665903, 134337696, 134999046, 135988791, 137003403, 144204752, 160963825, 162177716, 164806376, 166265868, 170465345, 175268115, 176267073, 177013106, 179150401, 210279669
|
|||
ChEBI ID |
CHEBI:2637
|
|||
ADReCS Drug ID | BADD_D00103 ; BADD_D00104 | |||
SuperDrug ATC ID |
D06AX12; J01GB06; S01AA21
|
|||
SuperDrug CAS ID |
cas=037517285
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium longum was decreased by Amikacin hydrate (adjusted p-values: 7.69E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Amikacin hydrate (adjusted p-values: 2.38E-03). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Coprococcus comes was decreased by Amikacin hydrate (adjusted p-values: 1.11E-04). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Amikacin hydrate (adjusted p-values: 5.57E-04). | |||
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia intestinalis was decreased by Amikacin hydrate (adjusted p-values: 2.42E-04). | |||
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus bromii was decreased by Amikacin hydrate (adjusted p-values: 6.00E-05). | |||
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus gnavus was decreased by Amikacin hydrate (adjusted p-values: 1.54E-03). | |||
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus torques was decreased by Amikacin hydrate (adjusted p-values: 8.28E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lactobacillus paracasei was decreased by Amikacin hydrate (adjusted p-values: 5.72E-05). | |||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Amikacin hydrate (adjusted p-values: 1.60E-04). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Amikacin hydrate (adjusted p-values: 3.70E-05). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) | Target Info | Binder | [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. | |||
REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.